Cis-Diammine-Dichloro-Platinum Single Drug and Combination Chemotherapy in the Treatment of Genitourinary Cancer

1980 ◽  
pp. 31-34
Author(s):  
G Stoter ◽  
H M Pinedo
Keyword(s):  
Combination Chemotherapy ◽  
Genitourinary Cancer ◽  
Single Drug

Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis

1996 ◽  
Vol 57 (11) ◽  
pp. 849-856 ◽  
Author(s):  
Li-Xing Zhang ◽  
Guan-Qing Kan ◽  
Do-Hua Tu ◽  
Li-Ya Wan ◽  
Abdul Rab Faruqi
Keyword(s):  
Combination Chemotherapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Single Drug ◽  
Dose Combination

Benefit/Risk Profile of Combined Antiplatelet Therapy with Ticlopidine and Aspirin

1991 ◽  
Vol 65 (05) ◽  
pp. 504-510 ◽  
Author(s):  
Raffaele De Caterina ◽  
Rosa Sicari ◽  
Walter Bernini ◽  
Guido Lazzerini ◽  
Giuliana Buti Strata ◽  
...  
Keyword(s):  
Platelet Function ◽  
Low Dose ◽  
Bleeding Time ◽  
Ex Vivo ◽  
Stable Coronary Artery Disease ◽  
High Dose ◽  
Single Drug ◽  
Before And After ◽  
Serum Thromboxane ◽  
Artery Disease

SummaryTiclopidine (T) and aspirin (ASA) are two antiplatelet drugs both capable of prolonging bleeding time (BT), with a different mechanism of action. A synergism in BT prolongation has been reported and is currently considered an argument for not recommending their combination. However, a profound suppression of platelet function might be a desirable counterpart of a marked prolongation of BT, with a possible use in selected clinical situations. We therefore studied ex vivo platelet function (aggregation by ADP 0.5-1-2.5 μM; adrenaline 0.75-2.5 μM; collagen 1.5-150 μg/ml; arachidonic acid 1 mM; PAF 1 μM; adrenaline 0.17 μM + ADP 0.62 μM; serum thromboxane ([TX]B2 generation) and BT (Mielke) in 6 patients with stable coronary artery disease receiving such combination. Patients underwent sequential laboratory evaluations at baseline, after 7 days of T 250 mg b.i.d., before and after the intravenous administration of ASA 500 mg, respectively, and, finally, after a minimum of 7 days of sole ASA oral administration (50 mg/day). The experimental design, therefore, allowed a comparison of T and ASA effects (2nd and 4th evaluation), and an assessment of the combination effect (3rd evaluation). Platelet aggregation in response to all doses of ADP was depressed more by T than by ASA. Conversely, responses to adrenaline, and arachidonate were affected more by ASA than by T. For all other agents, differences were not significant. T + ASA combination was more effective (p <0.05) than either treatment alone in depressing responses to high-dose collagen (% over control, mean ± SEM: T: 95 ± 3; ASA: 96 ± 5; T + ASA: 89 ± 4). Serum TXB2 (basal, ng/ml: 380 ± 54) did not change with T (372 ± 36), dropped to <1 ng/ml on ASA injection and slightly re-increased to 9.1 ± 3.1 ng/ml on oral low-dose ASA. BT (basal 7.4 ± 0.6 min) was affected similarly by T (9.2 ± 0.8) or ASA (9.7 ± 0.9) alone, but increased to 15.0 ± 0.7 min on combination treatment (106% increase over control). Thus, the strong synergism in BT prolongation by ASA-T combination has a counterpart in the inhibition of platelet function in response to strong stimuli such as high-dose collagen, not otherwise affected significantly by single-drug treatment. This effect is a possible rationale for the clinical evaluation of T + ASA combination.

Evaluations of Combination Chemotherapy(DAC-Tam) for Advanced Malignant Melanoma. Possible Patient Groups which may Show a Good Response Rate.

2001 ◽  
Vol 63 (5) ◽  
pp. 561-568
Author(s):  
Hideki KAMIYA ◽  
Hiroyuki KANOH ◽  
Naoki ICHIHASHI ◽  
Yoshiro ICHIKI ◽  
Hajime TAKAGI ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Combination Chemotherapy ◽  
Response Rate ◽  
Good Response Rate ◽  
Advanced Malignant Melanoma ◽  
Patient Groups
Sign in / Sign up

Export Citation Format

Share Document